Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 420, pseudogene (RNU6-420P) is a member of a large family of U6 small nuclear RNA pseudogenes in the human genome. The parental U6 small nuclear RNA (U6 snRNA) is an essential component of the major spliceosome, a large ribonucleoprotein complex responsible for removing introns from pre-mRNA via splicing, which is crucial for eukaryotic gene expression[1][3]. However, RNU6-420P is a pseudogene; these are typically non-functional genomic loci derived from functional genes that have accumulated disabling mutations[2]. Pseudogenes, including many derived from U6 snRNA, are present throughout the genome and usually do not encode functional RNA or protein. While some pseudogenes can have regulatory functions at the RNA level (such as acting as microRNA decoys or antisense RNAs), there is no direct evidence that RNU6-420P itself plays such a role[2]. RNU6-420P is not considered a therapeutic target, enzyme, receptor, or biomarker, nor is it associated with disease or drug interactions. Its presence reflects the evolutionary history and redundancy of the U6 snRNA gene family in vertebrates[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 420, pseudogene (RNU6-420P).